Showing 1 - 20 results of 23 for search 'Eric Chatelain', query time: 0.06s
Refine Results
-
1
Chagas disease research and development: Is there light at the end of the tunnel? by Eric Chatelain
Published 2017-01-01
Article -
2
Drug discovery and development for neglected diseases: the DNDi model by Eric Chatelain, Jean-Robert Ioset
Published 2011-03-01
Article -
3
-
4
-
5
A Multi-Species Phenotypic Screening Assay for Leishmaniasis Drug Discovery Shows That Active Compounds Display a High Degree of Species-Specificity by Laura M. Alcântara, Thalita C. S. Ferreira, Vanessa Fontana, Eric Chatelain, Carolina B. Moraes, Lucio H. Freitas-Junior
Published 2020-05-01
Article -
6
-
7
Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers for monitoring parasitolo... by Amanda Fortes Francisco, Ursula Saade, Shiromani Jayawardhana, Hans Pottel, Ivan Scandale, Eric Chatelain, Peter Liehl, John M Kelly, Maan Zrein
Published 2022-10-01
Article -
8
Correction: Identification of Compounds with Anti-Proliferative Activity against Strain 427 by a Whole Cell Viability Based HTS Campaign. by Melissa L. Sykes, Jonathan B. Baell, Marcel Kaiser, Eric Chatelain, Sarah R. Moawad, Danny Ganame, Jean-Robert Ioset, Vicky M. Avery
Published 2013-01-01
Article -
9
Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. by Melissa L Sykes, Jonathan B Baell, Marcel Kaiser, Eric Chatelain, Sarah R Moawad, Danny Ganame, Jean-Robert Ioset, Vicky M Avery
Published 2012-01-01
Article -
10
New metabolic signature for Chagas disease reveals sex steroid perturbation in humans and mice by Makan Golizeh, John Nam, Eric Chatelain, Yves Jackson, Leanne B. Ohlund, Asieh Rasoolizadeh, Fabio Vasquez Camargo, Louiza Mahrouche, Alexandra Furtos, Lekha Sleno, Momar Ndao
Published 2022-12-01
Article -
11
An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. by Jair L Siqueira-Neto, Seunghyun Moon, Jiyeon Jang, Gyongseon Yang, Changbok Lee, Hong Kee Moon, Eric Chatelain, Auguste Genovesio, Jonathan Cechetto, Lucio H Freitas-Junior
Published 2012-01-01
Article -
12
The Chagas disease study landscape: A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual partici... by Brittany J Maguire, Prabin Dahal, Sumayyah Rashan, Roland Ngu, Anca Boon, Colin Forsyth, Nathalie Strub-Wourgaft, Eric Chatelain, Fabiana Barreira, Sergio Sosa-Estani, Philippe J Guérin
Published 2021-08-01
Article -
13
Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study. by Nicolás Leonel González, Guillermo Moscatelli, Samanta Moroni, Griselda Ballering, Laura Jurado, Nicolás Falk, Andrés Bochoeyer, Alejandro Goldsman, María Grippo, Héctor Freilij, Facundo Garcia Bournissen, Eric Chatelain, Jaime Altcheh
Published 2022-12-01
Article -
14
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens by Irfan Ullah, Fanny Escudie, Ivan Scandale, Zoela Gilani, Gabrielle Gendron-Lepage, Fleur Gaudette, Charles Mowbray, Laurent Fraisse, Renée Bazin, Andrés Finzi, Walther Mothes, Priti Kumar, Eric Chatelain, Pradeep D. Uchil
Published 2024-03-01
Article -
15
Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series by Magali Van den Kerkhof, Philippe Leprohon, Dorien Mabille, Sarah Hendrickx, Lindsay B. Tulloch, Richard J. Wall, Susan Wyllie, Eric Chatelain, Charles E. Mowbray, Stéphanie Braillard, Marc Ouellette, Louis Maes, Guy Caljon
Published 2021-06-01
Article -
16
Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. by Jair L Siqueira-Neto, Ok-Ryul Song, Hyunrim Oh, Jeong-Hun Sohn, Gyongseon Yang, Jiyoun Nam, Jiyeon Jang, Jonathan Cechetto, Chang Bok Lee, Seunghyun Moon, Auguste Genovesio, Eric Chatelain, Thierry Christophe, Lucio H Freitas-Junior
Published 2010-01-01
Article -
17
Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns by Paul-Rémi Petit, Franck Touret, Jean-Sélim Driouich, Maxime Cochin, Léa Luciani, Ornéllie Bernadin, Caroline Laprie, Géraldine Piorkowski, Laurent Fraisse, Peter Sjö, Charles E. Mowbray, Fanny Escudié, Ivan Scandale, Eric Chatelain, Xavier de Lamballerie, Caroline Solas, Antoine Nougairède
Published 2024-05-01
Article -
18
Preclinical data do not support the use of amiodarone or dronedarone as antiparasitic drugs for Chagas disease at the approved human dosing regimen by Amanda F. Francisco, Gong Chen, Wen Wang, Melissa L. Sykes, Fanny Escudié, Ivan Scandale, Francisco Olmo, David M. Shackleford, Bilal Zulfiqar, Jadel M. Kratz, Thao Pham, Jessica Saunders, Meiyu Hu, Vicky M. Avery, Susan A. Charman, John M. Kelly, Eric Chatelain
Published 2023-09-01
Article -
19
Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity by Caio H. Franco, David C. Warhurst, Tapan Bhattacharyya, Ho Y.A. Au, Hai Le, Miriam A. Giardini, Bruno S. Pascoalino, Ana Claudia Torrecilhas, Lavinia M.D. Romera, Rafael Pedro Madeira, Sergio Schenkman, Lucio H. Freitas-Junior, Eric Chatelain, Michael A. Miles, Carolina B. Moraes
Published 2020-08-01
Article -
20
Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2 by Jean-Sélim Driouich, Maxime Cochin, Franck Touret, Paul-Rémi Petit, Magali Gilles, Grégory Moureau, Karine Barthélémy, Caroline Laprie, Thanaporn Wattanakul, Palang Chotsiri, Richard M. Hoglund, Joel Tarning, Laurent Fraisse, Peter Sjö, Charles E. Mowbray, Fanny Escudié, Ivan Scandale, Eric Chatelain, Xavier de Lamballerie, Caroline Solas, Antoine Nougairède
Published 2022-08-01
Article